Citi analyst Yigal Nochomovitz raised the firm’s price target on Travere Therapeutics (TVTX) to $48 from $34 and keeps a Buy rating on the shares. Citi also added an “upside 90-day catalyst watch” on Travere. The firm expects FDA approval by the action date of January 13, 2026, for Filspari for the treatment of focal segmental glomerulosclerosis. Citi believes “everything seems to be moving in a positive direction” for Travere following the Q3 report.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $40 from $30 at TD Cowen
- Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones
- Travere Therapeutics Reports Strong Q3 2025 Growth
- Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential
- Closing Bell Movers: Amazon soars to all-time highs on earnings